[go: up one dir, main page]

MA31564B1 - Inhibition par arni de l'expression du canal alpha-enac - Google Patents

Inhibition par arni de l'expression du canal alpha-enac

Info

Publication number
MA31564B1
MA31564B1 MA32484A MA32484A MA31564B1 MA 31564 B1 MA31564 B1 MA 31564B1 MA 32484 A MA32484 A MA 32484A MA 32484 A MA32484 A MA 32484A MA 31564 B1 MA31564 B1 MA 31564B1
Authority
MA
Morocco
Prior art keywords
alpha
expression
enac
canal
rnai inhibition
Prior art date
Application number
MA32484A
Other languages
English (en)
Inventor
Heeke Gino Van
Emma Hickman
Henry Luke Danahay
Pamela Tan
Anke Geick
Hans-Peter Vornlocher
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31564B1 publication Critical patent/MA31564B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSITIONS ET DES MÉTHODES PERMETTANT DE MODULER L'EXPRESSION DU CANAL ALPHA-ENAC ET, PLUS PARTICULIÈREMENT, DE RÉGULER À LA BAISSE L'EXPRESSION DU CANAL ALPHA-ENAC À L'AIDE D'OLIGONUCLÉOTIDES MODIFIÉS PAR VOIE CHIMIQUE.
MA32484A 2007-06-15 2010-01-07 Inhibition par arni de l'expression du canal alpha-enac MA31564B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07110376 2007-06-15
EP07114265 2007-08-13

Publications (1)

Publication Number Publication Date
MA31564B1 true MA31564B1 (fr) 2010-08-02

Family

ID=40130244

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32484A MA31564B1 (fr) 2007-06-15 2010-01-07 Inhibition par arni de l'expression du canal alpha-enac

Country Status (26)

Country Link
US (12) US7718632B2 (fr)
EP (7) EP2223694B1 (fr)
JP (6) JP5485146B2 (fr)
KR (2) KR101821081B1 (fr)
CN (1) CN101778941B (fr)
AR (1) AR066984A1 (fr)
AU (1) AU2008263876B2 (fr)
BR (1) BRPI0813680A8 (fr)
CA (1) CA2690674C (fr)
CL (1) CL2008001756A1 (fr)
CO (1) CO6251331A2 (fr)
CR (1) CR11136A (fr)
CU (1) CU23774A3 (fr)
EA (1) EA200901653A1 (fr)
EC (1) ECSP099794A (fr)
ES (6) ES2432643T3 (fr)
GT (1) GT200900315A (fr)
IL (1) IL202366A0 (fr)
MA (1) MA31564B1 (fr)
MX (1) MX2009013609A (fr)
PE (1) PE20090942A1 (fr)
SG (3) SG10201601846VA (fr)
SV (1) SV2009003434A (fr)
TN (1) TN2009000521A1 (fr)
TW (3) TWI552753B (fr)
WO (1) WO2008152131A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050058982A1 (en) 2002-07-26 2005-03-17 Chiron Corporation Modified small interfering RNA molecules and methods of use
KR100473148B1 (ko) * 2002-11-27 2005-03-10 (주)텔리언 버스트모드 패킷 전달을 위한 정합장치 및 방법
CA2581651C (fr) * 2004-10-01 2014-12-16 Novartis Vaccines And Diagnostics, Inc. Arn modifie marque avec du cholesterol
US8765704B1 (en) 2008-02-28 2014-07-01 Novartis Ag Modified small interfering RNA molecules and methods of use
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
CN102292443A (zh) * 2008-11-26 2011-12-21 默沙东公司 使用短干扰核酸(siNA)的RNA干扰介导的上皮钠通道(ENaC)基因表达的抑制
EP2756845B1 (fr) * 2009-04-03 2017-03-15 Dicerna Pharmaceuticals, Inc. Procédés et compositions pour l'inhibition spécifique de KRAS par de l'ARN double brin asymétrique
CN103275978B (zh) * 2009-04-03 2014-10-29 百奥迈科生物技术有限公司 修饰的小干扰核酸及其制备方法
WO2010111891A1 (fr) * 2009-04-03 2010-10-07 北京大学 Molécule modifiée d'acide oligo-nucléique, procédé d'élaboration et utilisations de celle-ci
US20120207818A1 (en) * 2009-07-14 2012-08-16 Shinohara Fumikazu Composition for suppressing expression of target gene
EP2488210A4 (fr) * 2009-10-12 2014-04-30 Smith Holdings Llc Procédés et compositions de modulation de l'expression génique en utilisant des médicaments à base d'oligonucléotides administrés in vivo ou in vitro
EP3000885B1 (fr) 2009-12-18 2018-07-25 Arrowhead Pharmaceuticals, Inc. Compositions organiques de traitement des pathologies liées à hsf1
KR20190122893A (ko) 2010-04-23 2019-10-30 애로우헤드 파마슈티컬스 인코포레이티드 베타-ＥＮａＣ-관련 질환을 치료하기 위한 유기 조성물
WO2012138416A1 (fr) 2011-04-08 2012-10-11 Bio-Rad Laboratories, Inc. Mélanges de réaction pcr à activité non spécifique réduite
CA2871089A1 (fr) 2011-04-20 2012-10-26 Smith Holdings, Llc Procedes et compositions de modulation de l'expression des genes a l'aide de composants qui sont auto-assembles dans des cellules et qui produisent une activite d'arni
CA2847283C (fr) 2011-09-02 2023-03-14 Novartis Ag Compositions organiques de traitement de maladies associees a hsf1
MX2019004909A (es) 2016-11-01 2019-08-12 Arrowhead Pharmaceuticals Inc Ligandos de integrina alfa-v beta-6 y usos de los mismos.
US10590416B2 (en) * 2017-07-06 2020-03-17 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of alpha-ENaC and methods of use
US20210180057A1 (en) * 2017-10-31 2021-06-17 Ionis Pharmaceuticals, Inc. MODULATORS OF ENaC EXPRESSION
IL274300B2 (en) * 2017-11-01 2024-09-01 Arrowhead Pharmaceuticals Inc Alpha v beta 6 integrin ligands, compositions comprising same and uses thereof
CN109364248B (zh) * 2018-10-16 2021-05-18 哈尔滨医科大学 ENaC及其抑制剂在预防、缓解和/或治疗动脉粥样硬化中的应用
US20220339136A1 (en) * 2019-08-30 2022-10-27 United States Government As Represented By The Department Of Veterans Affairs Liposomal troponoid compound formulations
US11957178B2 (en) 2021-11-15 2024-04-16 Apackaging Group Llc Aerosol actuator

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4426330A (en) * 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4837026A (en) * 1985-10-03 1989-06-06 Rajakhyaksha Vithal J Transdermal and systemic preparation and method
DE3604625C2 (de) * 1986-02-14 1994-01-20 Bmw Rolls Royce Gmbh Gasturbine
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US5451670A (en) * 1987-12-09 1995-09-19 City Of Hope Restriction fragment length polymorphism test for haplotyping domesticated fowl
GB8824593D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
US5013566A (en) * 1988-12-19 1991-05-07 Sampson Michael James Process for obtaining improved yields from plants used for hay making by using a coating agent
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5356633A (en) * 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5665710A (en) * 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
JP3220180B2 (ja) * 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
JP3351476B2 (ja) * 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
AU6044994A (en) * 1993-02-19 1994-09-14 Nippon Shinyaku Co. Ltd. Glycerol derivative, device and pharmaceutical composition
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
CA2137297C (fr) * 1993-12-06 2000-04-18 Tsuyoshi Miyazaki Vesicule reactive et vesicule fonctionnelle fixee a une substance
JP3543347B2 (ja) * 1994-01-24 2004-07-14 日本油脂株式会社 点火薬造粒物の製造方法
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5756122A (en) 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
WO1997004787A1 (fr) 1995-08-01 1997-02-13 Novartis Ag Compositions d'oligonucleotides et de liposomes
US5858397A (en) 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US6218108B1 (en) * 1997-05-16 2001-04-17 Research Corporation Technologies, Inc. Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor
US5865710A (en) * 1996-08-01 1999-02-02 Wilson-Hyde; Cynthia Step aerobic platform
CA2283293A1 (fr) 1997-03-11 1998-09-17 Yale University Procede de diagnostic et de traitement d'etats pathologiques resultant d'un transport ionique deficient tels que le pseudo-hypoaldosteronisme de type 1 (pha1)
US6887906B1 (en) * 1997-07-01 2005-05-03 Isispharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US5976849A (en) * 1998-02-05 1999-11-02 Zeneca Limited Human E3 ubiquitin protein ligase
WO2000053722A2 (fr) 1999-03-10 2000-09-14 Phogen Limited Administration de substances a des cellules
DK2813582T3 (en) * 2000-12-01 2017-07-31 Max-Planck-Gesellschaft Zur Förderung Der Wss E V Small RNA molecules that mediate RNA interference
US20030064385A1 (en) 2001-05-16 2003-04-03 Dressman Marlene Michelle Genes expressed in breast cancer as prognostic and therapeutic targets
WO2003057847A2 (fr) 2001-12-31 2003-07-17 Algos Therapeutics , Inc. Procedes et substances de modulation de l'enac-beta
US20050058982A1 (en) 2002-07-26 2005-03-17 Chiron Corporation Modified small interfering RNA molecules and methods of use
JP2004121218A (ja) 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
GB0218970D0 (en) 2002-08-14 2002-09-25 Creative Peptides Sweden Ab Fragments of Insulin c-peptide
EP2284266B1 (fr) * 2002-11-14 2013-11-06 Thermo Fisher Scientific Biosciences Inc. Molécule siRNA anti tp53
AU2003293124A1 (en) 2002-11-27 2004-06-23 Artesian Therapeutics, Inc. Heart failure gene determination and therapeutic screening
CN1694899B (zh) 2002-11-29 2011-07-06 赢创德固赛有限公司 生产甲硫氨酸的方法
DE10305213A1 (de) 2003-02-07 2004-08-26 Florian Prof. Dr.med. Lang Verwendung eines neuen Polymorphismus im hsgk1-Gen zur Diagnose der Hypertonie und Verwendung der sgk-Genfamilie zur Diagnose und Therapie des Long-Q/T-Syndroms
CA2520016A1 (fr) * 2003-03-31 2004-10-21 University Of Iowa Research Foundation Therapie pharmaco-genique des troubles associes au canal sodique epithelial
US7723509B2 (en) * 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
AU2003224132A1 (en) 2003-04-24 2004-11-19 Galapagos Genomics N.V. Effective sirna knock-down constructs
US20050256071A1 (en) * 2003-07-15 2005-11-17 California Institute Of Technology Inhibitor nucleic acids
JP4530335B2 (ja) * 2004-02-03 2010-08-25 独立行政法人科学技術振興機構 膀胱に発現する上皮型ナトリウムチャネルに対する阻害薬
CN101052717A (zh) * 2004-05-11 2007-10-10 α基因株式会社 诱发rna干扰的多核苷酸以及使用该多核苷酸的基因表达抑制方法
SE0402832D0 (sv) * 2004-11-18 2004-11-18 Astrazeneca Ab Methods
US20060166234A1 (en) * 2004-11-22 2006-07-27 Barbara Robertson Apparatus and system having dry control gene silencing compositions
WO2006066158A2 (fr) * 2004-12-14 2006-06-22 Alnylam Pharmaceuticals, Inc. Modulation et utilisations de l'arni de mll-af4
US8101741B2 (en) * 2005-11-02 2012-01-24 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
WO2007070509A2 (fr) * 2005-12-13 2007-06-21 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Agents inhibiteurs du canal sodium epithelial et utilisations
KR101133799B1 (ko) 2006-08-18 2012-04-24 에프. 호프만-라 로슈 아게 폴리뉴클레오타이드의 생체내 전달을 위한 다가접합체
SG166778A1 (en) 2006-10-11 2010-12-29 Max Planck Gesellschaft Influenza targets
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)

Also Published As

Publication number Publication date
CR11136A (es) 2010-01-20
US20100190714A1 (en) 2010-07-29
US10544418B2 (en) 2020-01-28
JP6680728B2 (ja) 2020-04-15
JP2022188234A (ja) 2022-12-20
AU2008263876B2 (en) 2012-04-12
EA200901653A1 (ru) 2010-06-30
US9914927B2 (en) 2018-03-13
US20180148726A1 (en) 2018-05-31
EP2223695B1 (fr) 2013-07-24
JP5719047B2 (ja) 2015-05-13
JP6193906B2 (ja) 2017-09-06
BRPI0813680A2 (pt) 2015-01-06
US20220235361A1 (en) 2022-07-28
KR101821081B1 (ko) 2018-01-23
US20160376599A1 (en) 2016-12-29
EP2171059A2 (fr) 2010-04-07
EP2223693A1 (fr) 2010-09-01
US20100216971A1 (en) 2010-08-26
ECSP099794A (es) 2010-01-29
IL202366A0 (en) 2011-08-01
MX2009013609A (es) 2010-01-20
KR101653008B1 (ko) 2016-08-31
JP2020094063A (ja) 2020-06-18
AU2008263876A1 (en) 2008-12-18
KR20100039335A (ko) 2010-04-15
TW201636027A (zh) 2016-10-16
SG10201404955RA (en) 2014-10-30
JP7157775B2 (ja) 2022-10-20
US7939508B2 (en) 2011-05-10
EP2223692A1 (fr) 2010-09-01
EP2224004A1 (fr) 2010-09-01
US7718632B2 (en) 2010-05-18
US7943592B2 (en) 2011-05-17
US20200157550A1 (en) 2020-05-21
TWI552753B (zh) 2016-10-11
WO2008152131A3 (fr) 2009-05-28
EP2223692B1 (fr) 2013-07-24
US8168606B2 (en) 2012-05-01
CO6251331A2 (es) 2011-02-21
ES2432644T3 (es) 2013-12-04
US20150284726A1 (en) 2015-10-08
US8119612B2 (en) 2012-02-21
US11208662B2 (en) 2021-12-28
ES2439277T3 (es) 2014-01-22
CL2008001756A1 (es) 2009-02-20
KR20160105530A (ko) 2016-09-06
EP2223694B1 (fr) 2013-07-24
EP2223695A1 (fr) 2010-09-01
US9074212B2 (en) 2015-07-07
EP2224005B1 (fr) 2013-09-11
US20090156529A1 (en) 2009-06-18
CU23774A3 (es) 2012-02-15
ES2432532T3 (es) 2013-12-04
TW201524510A (zh) 2015-07-01
GT200900315A (es) 2011-10-05
AR066984A1 (es) 2009-09-23
EP2223694A1 (fr) 2010-09-01
BRPI0813680A8 (pt) 2018-08-28
BRPI0813680B1 (pt) 2018-02-06
PE20090942A1 (es) 2009-08-05
CA2690674A1 (fr) 2008-12-18
WO2008152131A2 (fr) 2008-12-18
SG169988A1 (en) 2011-04-29
TWI629063B (zh) 2018-07-11
JP2015145393A (ja) 2015-08-13
EP2223693B1 (fr) 2013-07-24
TN2009000521A1 (en) 2011-03-31
SV2009003434A (es) 2011-03-23
JP2010530369A (ja) 2010-09-09
US20100210514A1 (en) 2010-08-19
CN101778941A (zh) 2010-07-14
CN101778941B (zh) 2013-05-22
US20220112505A1 (en) 2022-04-14
ES2432643T3 (es) 2013-12-04
EP2224005A1 (fr) 2010-09-01
US20100210513A1 (en) 2010-08-19
ES2432157T3 (es) 2013-12-02
EP2224004B1 (fr) 2013-07-24
TW200911989A (en) 2009-03-16
JP5485146B2 (ja) 2014-05-07
CA2690674C (fr) 2018-09-11
JP2017222704A (ja) 2017-12-21
ES2432158T3 (es) 2013-12-02
US9476052B2 (en) 2016-10-25
TWI444474B (zh) 2014-07-11
SG10201601846VA (en) 2016-04-28
JP2014129373A (ja) 2014-07-10
US20100216972A1 (en) 2010-08-26

Similar Documents

Publication Publication Date Title
MA31564B1 (fr) Inhibition par arni de l'expression du canal alpha-enac
EA200801959A1 (ru) Высокоразветвленный полипропилен
EP2032715A4 (fr) Méthodes et matières pour l'élaboration de simvastatine et de ses composés
CR20110684A (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
CY1114926T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
MA32934B1 (fr) Combinaisons inhibitrices hsp90
EP2198039A4 (fr) Micro-organisme modifié pour produire de l'isopropanol
CY1112558T1 (el) Ενωσεις ν-μεθυλαμινομεθυλο ισοϊνδολης και συνθεσεις που τις περιλαμβανουν και μεθοδοι χρησης τους
DE602007012559D1 (de) H die schleimhaut
MY162157A (en) Substituted indole mcl-1 inhibitors
CR10680A (es) Composiciones de inhibidores de chk1
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
CY1110943T1 (el) Νεα μεθοδος διαχωρισμου των εναντιομερων του (3,4-διμεθοξυδικυκλο[4.2.0]οκτα-1,3,5-τριεν-7-υλ) νιτριλιου και εφαρμογη στη συνθεση της ιβαβραδινης
BRPI0814772A2 (pt) Indazóis substituídos por 5-piridinona
EA201170640A1 (ru) Дизамещенные фталазины-антагонисты сигнального пути hedgehog
WO2007100777A3 (fr) Méthodes pour le traitement du tdah et de troubles apparentés
MY156691A (en) 2-(r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline from 1
UA110332C2 (en) Use of 2,3-dihydroxypropyldodecanoate for treatment of seborrhea
FR2905600B1 (fr) Traitement des vertiges par l'acetyl-l-leucine.
TR201109686T2 (tr) Olmesartan'ın Farmasötik Bileşimleri.
WO2009151618A3 (fr) Procédés et compositions pour traiter la maladie d'alzheimer
AU2018256632A1 (en) RNAi inhibition of alpha-ENaC expression
ATE479691T1 (de) 4,5,6,7-tetrahydrothienoä2,3-cüpyridine als h3- modulatoren
MX2009010812A (es) Derivados 4-dodeceno como ingredientes aromatizantes.